1. Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Kurt Miller 
European Urology Supplements 
Volume 8, Issue 1, Pages (January 2009)
DOI: /j.eursup
Copyright © 2008 European Association of Urology Terms and Conditions

2. Fig. 1
Overall survival in the TAX 327 study. Adapted from Berthold et al [5]. Reprinted with permission from American Society of Clinical Oncology. © 2008 All rights reserved.
European Urology Supplements 2009 8, 36-45DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

3. Fig. 2
Overall survival and prostate-specific antigen (PSA) response in the Androgen-Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere (ASCENT) phase 2 trial. Adapted from Beer et al [7]. Reprinted with permission from American Society of Clinical Oncology. © 2008 All rights reserved.
European Urology Supplements 2009 8, 36-45DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

4. Fig. 3
Overall survival with ZD mg or 15mg versus placebo. Adapted from James et al [30]. Reprinted with permission from Elsevier.
European Urology Supplements 2009 8, 36-45DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

5. Fig. 4
The ZD4054 ENdoTHelin A USE (ENTHUSE) phase 3 clinical trials programme.
European Urology Supplements 2009 8, 36-45DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions